Dosage research on Wolverine Stack

Preclinical research dose ranges

In published preclinical research on the individual components, BPC-157 rodent dose ranges have most commonly fallen in the 1 to 10 microgram per kilogram range delivered intraperitoneally, intragastrically, or subcutaneously (with the range extending to 10 nanograms per kilogram at the low end and 10 milligrams per kilogram at the high end across the broader literature). TB-500 / thymosin beta-4 rodent dose ranges have most commonly fallen in the 6 to 24 milligrams per kilogram range delivered intraperitoneally or intravenously for systemic endpoints.

No published combined-administration pharmacology study of BPC-157 and TB-500 in a fixed-ratio formulation has appeared in the indexed research literature. The stacking convention in research-community practice traces to the complementary mechanistic profiles (BPC-157 acting on the VEGFR2-Akt-eNOS pathway, TB-500 acting on actin-cytoskeleton modulation) rather than to peer-reviewed comparative head-to-head or combination-arm trials.

The Ronin catalog supplies the stack at a 1:1 fixed ratio (5 mg of each per 10 mg vial). Investigators interested in the per-component dose-response curves would need separate single-compound vials rather than the pre-combined Wolverine Stack formulation.

Dose-response considerations from the published literature

The per-component published literatures have reported dose-response characteristics described in the individual BPC-157 and TB-500 dosage research pages. No combined-administration dose-response curve has appeared in the indexed published research literature. The research community continues to rely on the per-component literatures for dose-design inference when working with the Wolverine Stack formulation.

No Phase 1 or Phase 2 dose-ranging trial of the combined BPC-157 / TB-500 stack has appeared in the indexed clinical-trial literature at the time of writing.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised Wolverine Stack vial (5 mg BPC-157 + 5 mg TB-500) reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 5 mg per mL of combined formulation (2.5 mg per mL of each component). From this stock, a research aliquot of 0.1 mL contains 500 micrograms of combined formulation (250 micrograms of each component). Researchers working with the per-component microgram-per-kilogram (BPC-157) or milligram-per-kilogram (TB-500) dose ranges further dilute the stock to a working concentration appropriate to the model. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice for both components.

Research-protocol design considerations

Protocol-design choices in research using the BPC-157 / TB-500 combination reflect several recurring considerations. The fixed-ratio formulation is the central protocol-design decision: investigators interested in the contribution of each component to the combined effect would need to use separate vials (BPC-157 alone, TB-500 alone, combination, placebo) as separate arms rather than the pre-combined Wolverine Stack formulation.

The per-component dose-range mismatch (BPC-157 at microgram-per-kilogram, TB-500 at milligram-per-kilogram) is a consideration in the design rationale for the 1:1 mass-ratio formulation. The 1:1 mass ratio means the dose-per-component is identical in mass terms but corresponds to a roughly 1000-fold higher per-kilogram exposure of TB-500 relative to BPC-157 in published-rodent-dose-equivalent terms.

Investigators interested in matching published per-component dose-equivalents in their protocols would need to dose using separate vials rather than the fixed-ratio Wolverine Stack vial. The Wolverine Stack convenience is in single-vial reconstitution and storage for protocols that do not require precise per-component dose matching against the published per-component literatures.

References

1. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats. World Journal of Gastroenterology, 2024. [PMID 39325560]
2. Seiwerth S et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Pharmaceuticals, 2025. [PMID 40789979]
3. Malinda KM et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997. [PMID 9194528]
4. Bock-Marquette I et al. Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004. [PMID 15565145]
5. Sosne G et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research, 2002. [PMID 11950239]